Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Jul;97(3):783–794. doi: 10.1111/j.1476-5381.1989.tb12017.x

GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.

P Lumley 1, B P White 1, P P Humphrey 1
PMCID: PMC1854582  PMID: 2527074

Abstract

1. The thromboxane A2 (TP)-receptor blocking activity and specificity of action of GR32191 ([1R-[1 alpha(Z),2 beta,3 beta,5 alpha]]-(+)-7-[5-([1,1'-biphenyl] -4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptoni c acid has been evaluated in human platelets and various smooth muscle preparations, both vascular and non-vascular, from a range of species including man. 2. Utilising a platelet counting method to assess aggregation the drug was found to antagonise, in a surmountable manner, human platelet aggregation produced by the TP-receptor agonists, U-46619, EP171 and SQ26655, in whole blood and physiological buffer, with pA2 values of approximately 8.3 and 8.7 in the two media respectively. In the presence of GR32191 the rate of aggregation induced by U-46619 was slowed. 3. The effect of GR32191 upon U-46619-induced platelet shape change and aggregation in platelet-rich plasma was evaluated utilising a turbidometric technique. Both shape change and aggregation were antagonised by GR32191. At relatively high concentrations of the drug a slowing of aggregation and shape change to U-44619 was seen and an unsurmountable antagonism became apparent. 4. The action of GR32191 upon human platelets was specific with platelet aggregation induced by adenosine 5'-diphosphate, platelet activating factor, vasopressin and adrenaline and the inhibitory effects of prostacylin (PGI2), prostaglandin D2 (PGD2) and N-ethylcarboxamide-adenosine (NECA) being unaffected by concentrations of the drug as high as 10 microM. Furthermore, at concentrations of up to 100 microM, the drug itself produced no shape change or aggregation, of human platelets. 5. GR32191 also specifically and potently antagonised in a competitive, surmountable manner the contractile actions of U-46619 upon human vascular smooth muscle and antagonised U-46619-induced contractions of vascular and airways smooth muscle preparations from rat, dog, guinea-pig and rabbit with varying potency. This is discussed in terms of possible heterogeneity of TP-receptors. 6. GR32191 therefore represents a highly potent and specific TP-receptor blocking drug. This profile of action, coupled to its long duration of effect in man described elsewhere, make it an ideal drug tool for elucidating the physiological and pathophysiological role of thromboxane A2.

Full text

PDF
783

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Armstrong R. A., Jones R. L., Peesapati V., Will S. G., Wilson N. H. Competitive antagonism at thromboxane receptors in human platelets. Br J Pharmacol. 1985 Mar;84(3):595–607. doi: 10.1111/j.1476-5381.1985.tb16139.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Armstrong R. A., Jones R. L., Wilson N. H. Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br J Pharmacol. 1983 Aug;79(4):953–964. doi: 10.1111/j.1476-5381.1983.tb10541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Best L. C., McGuire M. B., Martin T. J., Preston F. E., Russell R. G. Effects of epoxymethano analogues of prostaglandin endoperoxides on aggregation, on release of 5-hydroxytryptamine and on the metabolism of 3',5'-cyclic AMP and cyclic GMP in human platelets. Biochim Biophys Acta. 1979 Mar 22;583(3):344–351. doi: 10.1016/0304-4165(79)90458-6. [DOI] [PubMed] [Google Scholar]
  5. Blinks J. R. Convenient apparatus for recording contractions of isolated heart muscle. J Appl Physiol. 1965 Jul;20(4):755–757. doi: 10.1152/jappl.1965.20.4.755. [DOI] [PubMed] [Google Scholar]
  6. Blinks J. R. Evaluation of the cardiac effects of several beta adrenergic blocking agents. Ann N Y Acad Sci. 1967 Feb 10;139(3):673–685. doi: 10.1111/j.1749-6632.1967.tb41237.x. [DOI] [PubMed] [Google Scholar]
  7. Brittain R. T., Boutal L., Carter M. C., Coleman R. A., Collington E. W., Geisow H. P., Hallett P., Hornby E. J., Humphrey P. P., Jack D. AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2. Circulation. 1985 Dec;72(6):1208–1218. doi: 10.1161/01.cir.72.6.1208. [DOI] [PubMed] [Google Scholar]
  8. FURCHGOTT R. F., BHADRAKOM S. Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs. J Pharmacol Exp Ther. 1953 Jun;108(2):129–143. [PubMed] [Google Scholar]
  9. Friedhoff L. T., Manning J., Funke P. T., Ivashkiv E., Tu J., Cooper W., Willard D. A. Quantitation of drug levels and platelet receptor blockade caused by a thromboxane antagonist. Clin Pharmacol Ther. 1986 Dec;40(6):634–642. doi: 10.1038/clpt.1986.238. [DOI] [PubMed] [Google Scholar]
  10. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hammer R., Giraldo E., Schiavi G. B., Monferini E., Ladinsky H. Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sci. 1986 May 5;38(18):1653–1662. doi: 10.1016/0024-3205(86)90409-1. [DOI] [PubMed] [Google Scholar]
  12. Harris D. N., Hedberg A., Phillips M. B., Michel I. M., Goldenberg H. J., Liu E. C. 7-Oxabicycloheptane analogs: modulators of the arachidonate cascade. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:482–486. [PubMed] [Google Scholar]
  13. Humphrey P. P., Feniuk W., Perren M. J., Connor H. E., Oxford A. W., Coates L. H., Butina D. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol. 1988 Aug;94(4):1123–1132. doi: 10.1111/j.1476-5381.1988.tb11630.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jones R. L., Peesapati V., Wilson N. H. Antagonism of the thromboxane-sensitive contractile systems of the rabbit aorta, dog saphenous vein and guinea-pig trachea. Br J Pharmacol. 1982 Jul;76(3):423–438. doi: 10.1111/j.1476-5381.1982.tb09236.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kattelman E. J., Venton D. L., Le Breton G. C. Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thromb Res. 1986 Feb 15;41(4):471–481. doi: 10.1016/0049-3848(86)91692-0. [DOI] [PubMed] [Google Scholar]
  16. Keery R. J., Lumley P. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br J Pharmacol. 1988 Jul;94(3):745–754. doi: 10.1111/j.1476-5381.1988.tb11584.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kenakin T. P. The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev. 1984 Sep;36(3):165–222. [PubMed] [Google Scholar]
  18. Kennedy I., Coleman R. A., Humphrey P. P., Levy G. P., Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins. 1982 Nov;24(5):667–689. doi: 10.1016/0090-6980(82)90036-3. [DOI] [PubMed] [Google Scholar]
  19. Kondo K., Seo R., Kitagawa T., Omawari N., Kira H., Okegawa T., Kawasaki A. Preventive effect of ONO-3708 on thrombosis and vasospasms in vitro and in vivo. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:423–426. [PubMed] [Google Scholar]
  20. Le Breton G. C., Venton D. L., Enke S. E., Halushka P. V. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci U S A. 1979 Aug;76(8):4097–4101. doi: 10.1073/pnas.76.8.4097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Leff P., Martin G. R. Peripheral 5-HT2-like receptors. Can they be classified with the available antagonists? Br J Pharmacol. 1986 Jul;88(3):585–593. doi: 10.1111/j.1476-5381.1986.tb10239.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lumley P., Humphrey P. P. A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro. J Pharmacol Methods. 1981 Sep;6(2):153–166. doi: 10.1016/0160-5402(81)90038-3. [DOI] [PubMed] [Google Scholar]
  23. Narumiya S., Okuma M., Ushikubi F. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species. Br J Pharmacol. 1986 Jun;88(2):323–331. doi: 10.1111/j.1476-5381.1986.tb10208.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Nicolaou K. C., Magolda R. L., Smith J. B., Aharony D., Smith E. F., Lefer A. M. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2566–2570. doi: 10.1073/pnas.76.6.2566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ogletree M. L., Harris D. N., Greenberg R., Haslanger M. F., Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther. 1985 Aug;234(2):435–441. [PubMed] [Google Scholar]
  26. Patscheke H., Staiger C., Neugebauer G., Kaufmann B., Strein K., Endele R., Stegmeier K. The pharmacokinetic and pharmacodynamic profiles of the thromboxane A-2 receptor blocker BM 13.177. Clin Pharmacol Ther. 1986 Feb;39(2):145–150. doi: 10.1038/clpt.1986.25. [DOI] [PubMed] [Google Scholar]
  27. Steinsland O. S., Hieble J. P. Dopaminergic inhibition of adrenergic neurotransmission as a model for studies on dopamine receptor mechanisms. Science. 1978 Jan 27;199(4327):443–445. doi: 10.1126/science.22933. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES